Sai Parenterals will acquire a majority stake in Bion Therapeutics India through its wholly owned subsidiary SP Analytics.
The company’s board had approved a proposal to acquire a majority state in Bion, a Hyderabad-based formulations company, the BSE was informed.
Bion will become a step-down subsidiary of SAI Parenterals on completion of the deal, which is expected before the end of this month in an all-cash deal.
The cost of the acquisition will be based on the valuation of Bion Therapeutics as determined by the independent valuer.
Bion was incorporated in 2005 to undertake testing, analysis and examination of pharmaceuticals, medicines, drugs and other materials. It posted a total revenue of ₹47 crore in the financial year 2025-26 and ₹29 crore in first of the current financial year.
Published on November 17, 2026




